1. A 48-year-old man is admitted with acute pancreatitis. The team is selecting an intravenous crystalloid for early goal-directed fluid resuscitation. Based on randomized trial evidence, which fluid is preferred and why?
A) 0.9% normal saline, because its higher chloride content accelerates clearance of inflammatory mediators
B) 5% dextrose in water, because free-water replacement best corrects the third-space losses of pancreatitis
C) Lactated Ringer's solution, because it reduces systemic inflammatory response activation associated with the hyperchloremic acidosis seen with large-volume saline
D) 0.45% half-normal saline, because a hypotonic fluid limits pancreatic interstitial edema
E) 3% hypertonic saline, because raising serum osmolality withdraws fluid from the inflamed pancreatic bed
ANSWER: C
Rationale:
Lactated Ringer's (LR) is the preferred resuscitation fluid in acute pancreatitis. LR is mildly buffered (lactate is metabolized to bicarbonate), which avoids the hyperchloremic metabolic acidosis produced by large-volume 0.9% saline. That acidosis is associated with greater systemic inflammatory response syndrome (SIRS — a generalized inflammatory state) activation, which is the basis for preferring LR over saline. Separately, the WATERFALL randomized controlled trial compared aggressive with moderate LR resuscitation and found that aggressive resuscitation caused more fluid overload without improving outcomes, so a moderate, goal-directed LR strategy is preferred.
Option A: Option A is incorrect: the high chloride load of normal saline promotes, rather than clears, inflammatory acidosis.
Option B: Option B is incorrect: dextrose in water is a free-water solution that does not provide the isotonic volume expansion needed for the third-space losses of pancreatitis.
Option D: Option D is incorrect: hypotonic half-normal saline is not an appropriate resuscitation fluid and does not limit pancreatic edema.
Option E: Option E is incorrect: hypertonic saline is not standard resuscitation therapy in acute pancreatitis and is not supported by trial evidence here.
2. A 55-year-old woman has CT-confirmed sterile necrotizing pancreatitis. She is hemodynamically stable with no evidence of infection. The intern asks whether prophylactic antibiotics should be started to prevent the necrosis from becoming infected. What is the correct guideline-based answer?
A) No — prophylactic antibiotics for sterile necrosis do not reduce mortality, infected necrosis, or need for intervention, and are discouraged
B) Yes — start a carbapenem to sterilize the necrotic tissue before bacteria can translocate
C) Yes — start a fluoroquinolone plus metronidazole as routine prophylaxis in all necrotizing disease
D) Yes — start prophylactic fluconazole because fungal superinfection is the dominant early threat
E) No antibiotics now, but begin them automatically once the necrosis becomes walled-off on imaging
ANSWER: A
Rationale:
Prophylactic antibiotics are not indicated for sterile necrotizing pancreatitis. Multiple randomized trials and meta-analyses show no reduction in mortality, infected necrosis rates, or need for intervention, and current guidelines explicitly discourage the practice; antibiotics are reserved for confirmed infected necrosis or concurrent cholangitis.
Option B: Option B is incorrect: there is no benefit to "sterilizing" sterile necrosis with a carbapenem, and routine use selects for resistance and Clostridioides difficile infection.
Option C: Option C is incorrect: fluoroquinolone–metronidazole is used for confirmed infected necrosis, not as universal prophylaxis.
Option D: Option D is incorrect: empiric antifungal prophylaxis is not standard; antifungals are added only when fungal colonization is demonstrated.
Option E: Option E is incorrect: progression to a walled-off collection does not by itself indicate infection, and antibiotics are not started automatically on that basis.
3. A 60-year-old man with predicted severe acute pancreatitis needs nutritional support. He has a functioning gut and tolerates a nasogastric tube. Which approach is preferred and why?
A) Total parenteral nutrition, because resting the gut completely halts pancreatic enzyme secretion
B) Nil per os with intravenous fluids alone for at least 7 days to avoid stimulating the pancreas
C) Parenteral nutrition first, transitioning to enteral feeding only after CRP normalizes
D) Clear liquids advanced slowly to solids, because this stepwise progression lowers complication rates
E) Early enteral nutrition, because it maintains gut mucosal integrity, reduces bacterial translocation, and lowers infectious complications compared with parenteral nutrition
ANSWER: E
Rationale:
Early enteral nutrition (EN) is preferred in acute pancreatitis. EN maintains gut mucosal integrity, limits bacterial translocation, supports immune function, and reduces infectious complications relative to total parenteral nutrition (TPN) in multiple randomized trials; nasogastric and nasojejunal routes are comparable in efficacy and safety.
Option A: Option A is incorrect: TPN does not improve outcomes and is reserved for when enteral access cannot be established or is not tolerated.
Option B: Option B is incorrect: prolonged starvation is harmful and is not protective; feeding should begin early.
Option C: Option C is incorrect: CRP is an inflammatory marker that does not gate the route of nutrition, and enteral feeding should not be delayed waiting for it.
Option D: Option D is incorrect: when oral feeding resumes, starting with low-fat soft solids is appropriate, and the clear-liquid-to-solid progression does not reduce complications and prolongs hospitalization.
4. A patient with moderate-to-severe acute pancreatitis has poorly controlled pain despite intravenous acetaminophen. The resident hesitates to give an opioid, citing a concern that opioids will worsen the pancreatitis through sphincter of Oddi spasm. What is the most accurate guidance?
A) Avoid all opioids and rely on high-dose intravenous NSAIDs as monotherapy
B) Intravenous opioids are the primary analgesic class for moderate-to-severe pancreatitis pain, and the sphincter of Oddi concern with morphine has not proven clinically significant
C) Use only tramadol, because weak opioids do not affect the sphincter of Oddi
D) Withhold analgesia entirely so that worsening pain can serve as a marker of clinical deterioration
E) Give a single dose of intramuscular meperidine and then transition to oral acetaminophen
ANSWER: B
Rationale:
Intravenous opioids (commonly hydromorphone or morphine) are the primary analgesic class for moderate-to-severe acute pancreatitis pain. The historical concern that morphine causes clinically meaningful sphincter of Oddi spasm has not been validated in adequately powered comparative studies, so it should not prevent effective analgesia.
Option A: Option A is incorrect: NSAIDs and acetaminophen are useful adjuncts that reduce opioid requirements but are insufficient as monotherapy in moderate-to-severe disease.
Option C: Option C is incorrect: there is no requirement to restrict therapy to tramadol, and the sphincter argument does not justify it.
Option D: Option D is incorrect: deliberately withholding analgesia is inappropriate and unsafe; deterioration is monitored by clinical and laboratory parameters, not by uncontrolled pain.
Option E: Option E is incorrect: meperidine is not the favored agent, and a single intramuscular dose followed by oral acetaminophen would undertreat moderate-to-severe pain.
5. In acute pancreatitis, which clinical situation represents a validated indication for antibiotic therapy?
A) Persistent fever and leukocytosis attributable to systemic inflammatory response syndrome without documented infection
B) A rising C-reactive protein level on hospital day 3
C) Sterile necrosis exceeding 30% of the pancreas on contrast-enhanced CT
D) Confirmed infected necrosis, such as a positive culture on fine-needle aspiration or gas within a necrotic collection on imaging
E) Any case predicted to be severe by a validated scoring system at admission
ANSWER: D
Rationale:
The validated indications for antibiotics in acute pancreatitis are confirmed infected necrosis and concurrent cholangitis. Infected necrosis is identified by a positive culture on CT-guided fine-needle aspiration, or inferred from gas within a necrotic collection on imaging together with clinical deterioration.
Option A: Option A is incorrect: fever and leukocytosis frequently reflect SIRS (a sterile generalized inflammatory state) rather than infection and do not by themselves justify antibiotics.
Option B: Option B is incorrect: C-reactive protein is a nonspecific inflammatory marker and is not an indication to treat.
Option C: Option C is incorrect: the volume of sterile necrosis does not warrant antibiotics, since prophylaxis in sterile necrosis confers no benefit.
Option E: Option E is incorrect: predicted severity at admission does not establish infection and is not an antibiotic indication.
6. Pancreatic enzyme replacement therapy (PERT) preparations contain lipase, protease, and amylase. Which enzyme is the critical therapeutic component, and why?
A) Lipase, because fat digestion is most severely impaired in exocrine pancreatic insufficiency and fat malabsorption drives the greatest nutritional morbidity
B) Amylase, because carbohydrate malabsorption is the dominant cause of weight loss in this disorder
C) Protease, because protein maldigestion produces the steatorrhea characteristic of the disease
D) Amylase, because it is required to activate the other two enzymes within the duodenal lumen
E) Protease, because it protects lipase from degradation by gastric acid
ANSWER: A
Rationale:
Lipase is the critical component of PERT. Fat digestion is the most severely impaired process in exocrine pancreatic insufficiency (EPI), and fat malabsorption (steatorrhea) produces the greatest nutritional morbidity, including fat-soluble vitamin deficiency and weight loss; dosing is therefore expressed in lipase units.
Option B: Option B is incorrect: amylase deficiency is not the dominant driver of weight loss, and carbohydrate digestion is comparatively preserved.
Option C: Option C is incorrect: steatorrhea results from fat maldigestion (lipase deficiency), not protein maldigestion.
Option D: Option D is incorrect: amylase does not activate the other enzymes; this is a fabricated mechanism.
Option E: Option E is incorrect: protease does not shield lipase from acid; enteric coating and adequate duodenal pH protect the enzymes from acid denaturation.
7. A patient with exocrine pancreatic insufficiency continues to have steatorrhea. On questioning, she takes her enteric-coated enzyme microspheres as a single dose 30 minutes before each meal. What is the most appropriate correction to her regimen?
A) Switch her to a non-enteric-coated preparation taken on an empty stomach
B) Have her take the full dose 30 minutes after finishing each meal instead
C) Have her take the enzymes during the meal, splitting the dose across a large meal to improve mixing with the food bolus
D) Double the dose and keep taking it before the meal
E) Add the enzymes to hot liquids immediately before drinking to speed dissolution
ANSWER: C
Rationale:
PERT must be taken during the meal so that the enteric-coated microspheres mix with the food bolus in the stomach, empty with the chyme, and release enzymes in synchrony with nutrient delivery to the duodenum. Splitting the dose (half at the start, half midway) improves mixing during large meals.
Option A: Option A is incorrect: non-enteric-coated preparations are substantially less bioavailable because gastric acid denatures unprotected enzymes; taking them on an empty stomach worsens, not improves, digestion.
Option B: Option B is incorrect: dosing after the meal misses the bolus and produces poor mixing.
Option D: Option D is incorrect: increasing the dose without fixing the timing error is unlikely to resolve the problem and should follow verification of correct administration.
Option E: Option E is incorrect: exposing enteric-coated microspheres to hot liquids can disrupt the coating and inactivate enzymes prematurely.
8. A patient with exocrine pancreatic insufficiency has confirmed correct enzyme dosing and timing but still has inadequate fat absorption. Adding which adjunctive agent is most likely to improve the response to enzyme therapy, and by what mechanism?
A) An anticholinergic, by slowing gastric emptying so enzymes have more contact time
B) A bile acid sequestrant, by binding excess luminal fatty acids
C) A prokinetic, by accelerating delivery of enzymes to the colon
D) An H2 receptor antagonist taken only at bedtime, by suppressing nocturnal acid
E) A proton pump inhibitor, by raising duodenal pH above the threshold needed for enteric-coating dissolution and preventing acid inactivation of the enzymes
ANSWER: E
Rationale:
A proton pump inhibitor (PPI) is the appropriate adjunct when an adequately dosed and correctly timed PERT regimen still gives a suboptimal response. Pancreatic bicarbonate deficiency lowers duodenal pH; raising it above the dissolution threshold (about 5.5) with a PPI allows the enteric coating to dissolve and prevents acid denaturation of co-released enzymes.
Option A: Option A is incorrect: anticholinergics are not used to enhance PERT and carry their own adverse effects.
Option B: Option B is incorrect: bile acid sequestrants bind bile acids and would worsen fat malabsorption, not improve it.
Option C: Option C is incorrect: a prokinetic that speeds transit would reduce, not improve, enzyme–nutrient contact and absorption.
Option D: Option D is incorrect: while H2 blockers also raise gastric pH, a bedtime-only H2 antagonist does not reliably raise daytime postprandial duodenal pH, and a PPI is the standard, more effective choice.
9. A patient with long-standing, inadequately treated exocrine pancreatic insufficiency is most at risk for deficiency of which group of vitamins, and for what reason?
A) The water-soluble B vitamins, because pancreatic enzymes are required for their release from food
B) The fat-soluble vitamins A, D, E, and K, because impaired fat digestion disrupts the micellar absorption these vitamins depend on
C) Vitamin C specifically, because it competes with malabsorbed fat for transport
D) The fat-soluble vitamins, because pancreatic enzymes are the direct intestinal carriers for these vitamins
E) Vitamin B12 in isolation, because lipase is required for intrinsic factor binding
ANSWER: B
Rationale:
The fat-soluble vitamins A, D, E, and K (ADEK) are at greatest risk in inadequately treated EPI. Their absorption depends on micelle formation, which requires adequate luminal fat digestion; when steatorrhea is present, micellar uptake of these vitamins fails. Monitoring of 25-hydroxyvitamin D, vitamins A and E, and INR (a surrogate for vitamin K activity) is standard.
Option A: Option A is incorrect: water-soluble B vitamins do not depend on fat digestion for absorption and are not the primary deficiency here.
Option C: Option C is incorrect: vitamin C is water-soluble and does not compete with fat for transport.
Option D: Option D is incorrect: it names the right vitamins but states a false mechanism, because pancreatic enzymes are not vitamin carriers and the deficiency arises from failed micellar absorption secondary to fat maldigestion.
Option E: Option E is incorrect: B12 absorption depends on intrinsic factor and the terminal ileum, not on lipase.
10. Octreotide and lanreotide are effective in most functional gastroenteropancreatic neuroendocrine tumors. Through which receptor mechanism do these somatostatin analogues exert their secretory-inhibitory effect?
A) Competitive antagonism at G-protein-coupled serotonin receptors on tumor cells
B) Irreversible inhibition of tumor-cell adenylyl cyclase independent of any receptor
C) Activation of nuclear hormone receptors that downregulate peptide gene transcription
D) Agonism at G-protein-coupled somatostatin receptors, particularly the SSTR2 and SSTR5 subtypes that most functional tumors express at high density
E) Blockade of voltage-gated sodium channels that triggers vesicular hormone release
ANSWER: D
Rationale:
Octreotide and lanreotide are agonists at somatostatin receptors, which are G-protein-coupled receptors. Most functional gastroenteropancreatic neuroendocrine tumors express the SSTR2 and SSTR5 subtypes at high density, so these analogues suppress hormone secretion in the majority of cases and also exert antiproliferative effects through SSTR2.
Option A: Option A is incorrect: these drugs are somatostatin receptor agonists, not serotonin receptor antagonists.
Option B: Option B is incorrect: their effect is receptor-mediated, not a receptor-independent enzymatic inhibition.
Option C: Option C is incorrect: somatostatin receptors are cell-surface G-protein-coupled receptors, not nuclear hormone receptors.
Option E: Option E is incorrect: the mechanism is receptor agonism that reduces secretion, not sodium-channel blockade triggering release.
11. A patient with an inoperable insulinoma has recurrent hypoglycemia. Diazoxide is selected to suppress insulin secretion. What is its mechanism in the pancreatic beta cell?
A) It opens ATP-sensitive potassium channels, hyperpolarizing the beta cell so voltage-gated calcium channels stay closed and calcium-triggered insulin exocytosis is suppressed
B) It blocks ATP-sensitive potassium channels, depolarizing the beta cell and exhausting its insulin stores
C) It antagonizes the insulin receptor on peripheral tissues to raise blood glucose
D) It inhibits hepatic glucokinase, reducing glucose-stimulated insulin release
E) It activates somatostatin receptors on the beta cell to halt secretion
ANSWER: A
Rationale:
Diazoxide opens (activates) ATP-sensitive potassium (KATP) channels in pancreatic beta cells. The resulting potassium efflux hyperpolarizes the membrane, preventing the depolarization that opens voltage-gated calcium channels; without calcium influx, calcium-triggered insulin exocytosis is suppressed, raising blood glucose.
Option B: Option B inverts the mechanism: blocking KATP channels would depolarize the cell and stimulate insulin release, the opposite of the intended effect.
Option C: Option C is incorrect: diazoxide does not antagonize the peripheral insulin receptor.
Option D: Option D is incorrect: it does not act through glucokinase inhibition.
Option E: Option E is incorrect: KATP-channel opening, not somatostatin-receptor agonism, is the mechanism; somatostatin analogues are a separate (and less reliable) option for insulinoma.
12. A patient presents with profuse watery diarrhea, hypokalemia, and achlorhydria, and is diagnosed with a VIPoma. Which pharmacological therapy best controls the secretory diarrhea while surgical resection is planned?
A) A high-dose proton pump inhibitor, because excess gastric acid drives the diarrhea
B) Loperamide alone, because slowing transit corrects the underlying hormone excess
C) Octreotide, because suppressing vasoactive intestinal peptide secretion controls the fluid and electrolyte hypersecretion in most patients
D) Diazoxide, because opening beta-cell potassium channels reduces intestinal secretion
E) Oral pancreatic enzymes, because enzyme replacement counteracts the malabsorptive diarrhea
ANSWER: C
Rationale:
VIPoma produces the WDHA syndrome (watery diarrhea, hypokalemia, achlorhydria) through vasoactive intestinal peptide (VIP)-driven intestinal fluid and electrolyte hypersecretion. Octreotide suppresses VIP secretion and controls the diarrhea in roughly 80–90% of patients, allowing electrolyte stabilization before resection.
Option A: Option A is incorrect: the diarrhea is VIP-mediated secretory diarrhea, not acid-driven; indeed achlorhydria is part of the syndrome.
Option B: Option B is incorrect: loperamide does not address the hormonal driver and is inadequate as primary control.
Option D: Option D is incorrect: diazoxide targets insulin release in insulinoma and does not treat VIP-mediated secretion.
Option E: Option E is incorrect: this is a secretory, not malabsorptive, diarrhea, so pancreatic enzymes are not the treatment.
13. A severely malnourished patient is started on nutritional support and develops refeeding syndrome. Which electrolyte derangement is the hallmark and most dangerous element of this syndrome?
A) Hypernatremia from rapid dextrose-driven free-water shifts
B) Hyperkalemia from cellular potassium release during anabolism
C) Hypercalcemia from mobilization of skeletal calcium stores
D) Hypermagnesemia from impaired renal magnesium clearance
E) Hypophosphatemia, which impairs ATP production and can cause rhabdomyolysis, respiratory muscle failure, and cardiac arrhythmias
ANSWER: E
Rationale:
Hypophosphatemia is the hallmark and most dangerous feature of refeeding syndrome. As insulin drives glucose and amino acids into cells during anabolism, phosphate is consumed for ATP synthesis and shifts intracellularly; severe hypophosphatemia (serum phosphate below about 0.5 mmol/L) impairs ATP production and 2,3-DPG, causing rhabdomyolysis, respiratory muscle failure, hemolysis, and cardiac arrhythmias.
Option A: Option A is incorrect: refeeding causes intracellular shifts of phosphate, potassium, and magnesium, not hypernatremia.
Option B: Option B inverts the direction: insulin drives potassium into cells, producing hypokalemia, not hyperkalemia.
Option C: Option C is incorrect: hypercalcemia is not a defining feature of refeeding syndrome.
Option D: Option D inverts the direction: refeeding produces hypomagnesemia from intracellular shift, not hypermagnesemia.
14. Before initiating feeding in a high-risk malnourished patient, which vitamin must be supplemented to prevent a specific neurological complication, and which complication does it prevent?
A) Vitamin D, to prevent hypocalcemic seizures during refeeding
B) Thiamine, to prevent Wernicke encephalopathy as carbohydrate refeeding increases thiamine demand
C) Folate, to prevent the subacute combined degeneration seen with rapid refeeding
D) Vitamin B12, to prevent peripheral neuropathy precipitated by glucose loading
E) Vitamin K, to prevent intracranial hemorrhage during nutritional repletion
ANSWER: B
Rationale:
Thiamine (200–300 mg IV daily for the first few days) must be given before or alongside refeeding in high-risk malnourished patients. Carbohydrate refeeding sharply increases thiamine demand as a cofactor for glucose metabolism, and in a thiamine-depleted patient this can precipitate Wernicke encephalopathy.
Option A: Option A is incorrect: hypocalcemic seizures are not the characteristic refeeding complication that vitamin supplementation prevents here.
Option C: Option C is incorrect: folate does not prevent subacute combined degeneration, which is a B12-deficiency entity and not a refeeding-specific risk.
Option D: Option D is incorrect: B12 is not the vitamin given to prevent a refeeding neurological complication.
Option E: Option E is incorrect: vitamin K addresses coagulopathy, not a neurological refeeding complication.
15. A patient on long-term parenteral nutrition develops cholestasis consistent with PN-associated liver disease. A change in the intravenous lipid emulsion is considered. Which change is best supported, and why?
A) Switch to a pure soybean-oil emulsion, because its high n-6 fatty acid content is hepatoprotective
B) Eliminate all lipid from the regimen permanently to remove the hepatic lipid burden
C) Increase the dextrose calories to fully replace lipid calories indefinitely
D) Switch to a fish-oil-containing mixed-oil emulsion, because the n-3 fatty acids reduce the incidence of PN-associated liver disease and can reverse cholestasis
E) Add an oral bile acid sequestrant while continuing the soybean-oil emulsion unchanged
ANSWER: D
Rationale:
Mixed-oil emulsions incorporating fish oil (a source of anti-inflammatory n-3 fatty acids), along with olive oil and medium-chain triglycerides, are associated with improved hepatic outcomes; fish-oil-enriched emulsions reduce the incidence of PN-associated liver disease (PNALD) and can reverse established cholestasis.
Option A: Option A is incorrect: soybean-oil emulsions are rich in pro-inflammatory n-6 fatty acids and are implicated in PNALD, not protective.
Option B: Option B is incorrect: permanently eliminating lipid risks essential fatty acid deficiency and is not the supported strategy.
Option C: Option C is incorrect: indefinitely substituting dextrose for lipid causes its own metabolic and hepatic problems and is not the recommended fix.
Option E: Option E is incorrect: continuing the soybean-oil emulsion unchanged does not address the lipid composition that drives PNALD, and a sequestrant is not the established remedy.
16. A patient with chronic pancreatitis has neuropathic-type pain inadequately controlled on acetaminophen, and the team wishes to limit opioid exposure given coexisting alcohol use disorder. Which adjunct has randomized-trial support and an opioid-sparing rationale, and what is its mechanism?
A) Pregabalin, which modulates the voltage-gated calcium channel alpha-2-delta subunit to reduce central pain sensitization
B) A long-acting oral opioid scheduled around the clock as the first-line adjunct
C) An oral corticosteroid taper to suppress perineural inflammation
D) A muscarinic antagonist to reduce ductal pressure
E) A topical NSAID applied over the epigastrium
ANSWER: A
Rationale:
Pregabalin has randomized-controlled-trial support for modest benefit in chronic pancreatitis pain and is a useful opioid-sparing adjunct, an important consideration given the high baseline risk of opioid use disorder in this population. It acts by binding the alpha-2-delta subunit of voltage-gated calcium channels, reducing central pain sensitization.
Option B: Option B is incorrect: escalating to a scheduled long-acting opioid runs counter to the opioid-sparing goal and is not the preferred adjunct here.
Option C: Option C is incorrect: chronic systemic corticosteroids are not an established analgesic strategy for chronic pancreatitis and carry substantial harms.
Option D: Option D is incorrect: muscarinic antagonists are not a validated treatment for chronic pancreatitis pain.
Option E: Option E is incorrect: a topical NSAID does not address the central and ductal mechanisms of chronic pancreatitis pain and lacks supportive trial evidence in this setting.
17. A patient with carcinoid syndrome and hepatic metastases is scheduled for hepatic artery embolization. Which pharmacological measure is standard to prevent a life-threatening intraprocedural complication, and what complication does it prevent?
A) Prophylactic broad-spectrum antibiotics, to prevent septic shock from tumor manipulation
B) A preoperative beta-blocker infusion, to prevent hypertensive crisis from catecholamine release
C) High-dose octreotide given before induction and continued as an infusion during the procedure, to prevent carcinoid crisis from a surge of vasoactive mediators
D) Intravenous corticosteroids, to prevent an anaphylactoid reaction to the embolization agent
E) A calcium channel blocker, to prevent coronary vasospasm during mediator release
ANSWER: C
Rationale:
Patients with carcinoid syndrome undergoing surgery, anesthesia induction, or hepatic artery embolization are at risk for carcinoid crisis—a life-threatening surge of vasoactive mediators causing severe flushing, bronchospasm, and hemodynamic collapse. High-dose octreotide (for example, a 500-microgram IV bolus before induction followed by an infusion during the procedure) is the standard prophylaxis, and octreotide is also the treatment of choice for acute crisis.
Option A: Option A is incorrect: the threat is a mediator surge, not sepsis, so antibiotics do not address it.
Option B: Option B is incorrect: carcinoid crisis is driven by serotonin and other vasoactive mediators, not catecholamines, so a beta-blocker is not the preventive measure.
Option D: Option D is incorrect: the risk is mediator-driven hemodynamic collapse rather than a contrast/anaphylactoid reaction.
Option E: Option E is incorrect: a calcium channel blocker does not prevent carcinoid crisis and could worsen hypotension.
18. A patient with insulinoma on diazoxide develops peripheral edema and weight gain. This adverse effect is expected, and a specific co-medication is commonly used to manage it. What is the adverse effect, and what is the standard co-medication?
A) Hyperglycemia, managed by adding basal insulin
B) Hypertrichosis, managed by adding spironolactone
C) Hyperkalemia, managed by adding a potassium binder
D) Hypotension, managed by adding fludrocortisone
E) Sodium and fluid retention, managed by co-prescribing a diuretic such as hydrochlorothiazide
ANSWER: E
Rationale:
Diazoxide characteristically causes sodium and fluid retention, which can produce edema and weight gain; a thiazide diuretic such as hydrochlorothiazide is commonly co-prescribed to counter it (the thiazide also has a mild hyperglycemic effect that is complementary in this setting).
Option A: Option A is incorrect: although diazoxide can cause hyperglycemia if overdosed, the edema and weight gain described here reflect fluid retention, and insulin is not the management for that finding.
Option B: Option B is incorrect: hypertrichosis is a recognized long-term diazoxide effect, but it does not cause edema, and spironolactone is not its treatment.
Option C: Option C is incorrect: diazoxide is not characteristically associated with hyperkalemia.
Option D: Option D is incorrect: diazoxide causes fluid retention rather than hypotension requiring fludrocortisone.
19. A patient who underwent terminal ileal resection for Crohn's disease is being monitored for nutrient deficiency. Deficiency of which vitamin is most specifically expected, and what is the anatomical reason?
A) Folate, because folate is absorbed exclusively in the terminal ileum
B) Vitamin B12, because its absorption requires intrinsic factor and uptake by receptors in the terminal ileum, which has been resected
C) Iron, because iron absorption occurs predominantly in the terminal ileum
D) Vitamin C, because the terminal ileum is the principal site of ascorbate uptake
E) Calcium, because calcium absorption depends primarily on the terminal ileum
ANSWER: B
Rationale:
Vitamin B12 (cobalamin) absorption requires intrinsic factor (secreted by gastric parietal cells) and uptake by cubilin receptors in the terminal ileum; resection of the terminal ileum removes that uptake site, making B12 deficiency the specifically expected problem (this also disrupts bile acid recycling).
Option A: Option A is incorrect: folate is absorbed mainly in the proximal small intestine, not the terminal ileum.
Option C: Option C is incorrect: iron is absorbed predominantly in the duodenum and proximal jejunum.
Option D: Option D is incorrect: vitamin C is not specifically dependent on terminal ileal absorption.
Option E: Option E is incorrect: calcium is absorbed primarily in the proximal small intestine, so terminal ileal resection does not specifically cause calcium deficiency.
20. A patient meets criteria for high refeeding syndrome risk. Which feeding strategy is correct for the first days of nutritional support?
A) Begin feeding at full estimated caloric needs immediately, correcting any electrolyte abnormalities afterward as they appear
B) Withhold all nutrition until every electrolyte is supranormal, then start at full calories
C) Start at full calories but give prophylactic phosphate so levels cannot fall
D) Correct electrolytes to safe levels first, start at no more than about 10 kcal/kg/day, advance by roughly a third every two days while monitoring electrolytes, and give thiamine
E) Use parenteral nutrition exclusively at full calories, since the intravenous route prevents refeeding shifts
ANSWER: D
Rationale:
In high-risk patients, the protocol is to correct electrolytes to safe levels before feeding, initiate feeding at no more than approximately 10 kcal/kg/day (about half of estimated needs), advance cautiously by about a third every two days while monitoring potassium, magnesium, and phosphate, and supplement thiamine.
Option A: Option A is incorrect: starting at full calories is precisely what precipitates the dangerous insulin-driven electrolyte shifts.
Option B: Option B is incorrect: feeding should not be withheld until electrolytes are supranormal; they are corrected to safe levels and feeding then begins cautiously.
Option C: Option C is incorrect: prophylactic phosphate does not license full-calorie initiation, which remains unsafe.
Option E: Option E is incorrect: the route of nutrition does not prevent refeeding shifts; the rate of caloric delivery does.
21. Somatostatin analogues reliably control hormone excess in VIPoma and glucagonoma but are used more cautiously in insulinoma. What best explains this difference?
A) Insulinomas often lack SSTR2 (expressing SSTR3 and SSTR5 instead), so the response is less reliable, and somatostatin analogues can paradoxically worsen hypoglycemia by suppressing counter-regulatory glucagon
B) Insulinomas do not express any somatostatin receptors, so somatostatin analogues have no possible effect
C) Somatostatin analogues stimulate insulin release directly, which is dangerous in insulinoma
D) Insulinomas secrete vasoactive intestinal peptide rather than insulin, so the target is wrong
E) Somatostatin analogues are contraindicated in insulinoma because they cause rebound hyperglycemia in all patients
ANSWER: A
Rationale:
Insulinomas frequently express SSTR3 and SSTR5 without high SSTR2 density, so somatostatin analogues are less reliable than in VIPoma or glucagonoma; moreover, by suppressing counter-regulatory glucagon they can paradoxically worsen hypoglycemia, so they are used only under careful glucose monitoring (diazoxide is the more dependable pharmacological option).
Option B: Option B is incorrect: insulinomas do express somatostatin receptors—just a less favorable subtype profile—so the issue is reliability, not complete absence.
Option C: Option C is incorrect: somatostatin analogues suppress, not stimulate, hormone secretion.
Option D: Option D is incorrect: insulinomas secrete insulin; VIP secretion characterizes VIPoma.
Option E: Option E is incorrect: they are used cautiously rather than absolutely contraindicated, and the concern is worsening hypoglycemia, not universal rebound hyperglycemia.
22. A patient with short bowel syndrome and minimal residual absorptive surface requires enteral nutrition. Which formulation category is most appropriate, and on what principle?
A) A polymeric formula, because intact protein is best absorbed when absorptive surface is minimal
B) A standard fiber-enriched formula, because added fiber compensates for lost absorptive area
C) An elemental formula of free amino acids with minimal fat as medium-chain triglycerides, because predigested nutrients require the least absorptive and digestive capacity
D) An immune-modulating formula enriched with arginine and glutamine, because pharmaconutrition is proven superior in short bowel syndrome
E) A renal-disease formula, because reducing phosphate and potassium improves absorption across a short bowel
ANSWER: C
Rationale:
Elemental formulas provide free amino acids and minimal fat (largely as medium-chain triglycerides, which are absorbed without micelle formation), so they demand the least digestive and absorptive capacity and are reserved for severe malabsorption, short bowel syndrome, or minimal residual bowel.
Option A: Option A is incorrect: polymeric formulas contain intact protein appropriate for a functional gut, not for minimal absorptive surface.
Option B: Option B is incorrect: fiber does not compensate for lost absorptive area and is not the basis for formula selection here.
Option D: Option D is incorrect: immune-modulating "pharmaconutrition" formulas have shown heterogeneous or null results in large trials and are not established as superior in short bowel syndrome.
Option E: Option E is incorrect: a renal formula targets electrolyte content for kidney disease and does not address the absorptive limitation of short bowel.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.